Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

127.20 -5.89 (-4.42%)
Streaming Delayed Price Updated: 2:20 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Launch of Public Offering
From Abivax
Via GlobeNewswire
News headline image
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study ↗
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile. 
Via Benzinga
News headline image
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket ↗
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results. 
Via Benzinga
News headline image
Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential ↗
The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study. 
Via Stocktwits
News headline image
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Abivax Announces Results of its June 6, 2025 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
From Abivax
Via GlobeNewswire
News headline image
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
News headline image
Earnings Scheduled For March 24, 2025 ↗
 
Via Benzinga
News headline image
Abivax Announces Full Year 2024 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
From Abivax
Via GlobeNewswire
News headline image
Abivax Publishes 2025 Financial Calendar
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
From Abivax
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.